281 related articles for article (PubMed ID: 25099687)
1. Improving the serum stability of site-specific antibody conjugates with sulfone linkers.
Patterson JT; Asano S; Li X; Rader C; Barbas CF
Bioconjug Chem; 2014 Aug; 25(8):1402-7. PubMed ID: 25099687
[TBL] [Abstract][Full Text] [Related]
2. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
[TBL] [Abstract][Full Text] [Related]
3. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Shen BQ; Xu K; Liu L; Raab H; Bhakta S; Kenrick M; Parsons-Reponte KL; Tien J; Yu SF; Mai E; Li D; Tibbitts J; Baudys J; Saad OM; Scales SJ; McDonald PJ; Hass PE; Eigenbrot C; Nguyen T; Solis WA; Fuji RN; Flagella KM; Patel D; Spencer SD; Khawli LA; Ebens A; Wong WL; Vandlen R; Kaur S; Sliwkowski MX; Scheller RH; Polakis P; Junutula JR
Nat Biotechnol; 2012 Jan; 30(2):184-9. PubMed ID: 22267010
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates.
Jackson D; Atkinson J; Guevara CI; Zhang C; Kery V; Moon SJ; Virata C; Yang P; Lowe C; Pinkstaff J; Cho H; Knudsen N; Manibusan A; Tian F; Sun Y; Lu Y; Sellers A; Jia XC; Joseph I; Anand B; Morrison K; Pereira DS; Stover D
PLoS One; 2014; 9(1):e83865. PubMed ID: 24454709
[TBL] [Abstract][Full Text] [Related]
5. Engineering THIOMABs for site-specific conjugation of thiol-reactive linkers.
Bhakta S; Raab H; Junutula JR
Methods Mol Biol; 2013; 1045():189-203. PubMed ID: 23913148
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
7. Attachment Site Cysteine Thiol pK
Vollmar BS; Wei B; Ohri R; Zhou J; He J; Yu SF; Leipold D; Cosino E; Yee S; Fourie-O'Donohue A; Li G; Phillips GL; Kozak KR; Kamath A; Xu K; Lee G; Lazar GA; Erickson HK
Bioconjug Chem; 2017 Oct; 28(10):2538-2548. PubMed ID: 28885827
[TBL] [Abstract][Full Text] [Related]
8. Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability.
Sussman D; Westendorf L; Meyer DW; Leiske CI; Anderson M; Okeley NM; Alley SC; Lyon R; Sanderson RJ; Carter PJ; Benjamin DR
Protein Eng Des Sel; 2018 Feb; 31(2):47-54. PubMed ID: 29370435
[TBL] [Abstract][Full Text] [Related]
9. Tuning the Hydrolytic Stability of Next Generation Maleimide Cross-Linkers Enables Access to Albumin-Antibody Fragment Conjugates and tri-scFvs.
Forte N; Livanos M; Miranda E; Morais M; Yang X; Rajkumar VS; Chester KA; Chudasama V; Baker JR
Bioconjug Chem; 2018 Feb; 29(2):486-492. PubMed ID: 29384367
[TBL] [Abstract][Full Text] [Related]
10. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.
Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A
Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424
[TBL] [Abstract][Full Text] [Related]
11. One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies.
Shinmi D; Taguchi E; Iwano J; Yamaguchi T; Masuda K; Enokizono J; Shiraishi Y
Bioconjug Chem; 2016 May; 27(5):1324-31. PubMed ID: 27074832
[TBL] [Abstract][Full Text] [Related]
12. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
13. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
[TBL] [Abstract][Full Text] [Related]
14. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
[TBL] [Abstract][Full Text] [Related]
15. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
16. Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.
Jäger S; Wagner TR; Rasche N; Kolmar H; Hecht S; Schröter C
Bioconjug Chem; 2021 Aug; 32(8):1699-1710. PubMed ID: 34185508
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Disulfide Bond Rebridged Fab-Drug Conjugates Prepared Using a Dual Maleimide Pyrrolobenzodiazepine Cytotoxic Payload.
Ruddle BT; Fleming R; Wu H; Gao C; Dimasi N
ChemMedChem; 2019 Jun; 14(12):1185-1195. PubMed ID: 30980702
[TBL] [Abstract][Full Text] [Related]
18. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
19. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
[TBL] [Abstract][Full Text] [Related]
20. Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.
Ferhati X; Jiménez-Moreno E; Hoyt EA; Salluce G; Cabeza-Cabrerizo M; Navo CD; Compañón I; Akkapeddi P; Matos MJ; Salaverri N; Garrido P; Martínez A; Laserna V; Murray TV; Jiménez-Osés G; Ravn P; Bernardes GJL; Corzana F
J Am Chem Soc; 2022 Mar; 144(12):5284-5294. PubMed ID: 35293206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]